GLYCYRRHIZIC ACID GLYCOPEPTIDE WITH GLYCYL-L-PHENYLALANINE ELICITING ANTI-HIV-1 ACTIVITY Russian patent published in 2008 - IPC C07K9/00 C07J63/00 A61K38/14 A61P31/18 

FIELD: chemistry of peptides, virology.

SUBSTANCE: invention relates to novel chemical compounds, namely, to glycyrrhizic acid (GA) glycopeptide with glycyl-L-phenylalanine: 3-O-{2-O-[N-(β-D-glucopyranosyluronoyl)-glycyl-L-phenylalanine-N-(β-D-glucopyranosyluronoyl)-glycyl-L-phenylalanine)]}-(3β,20β)-11-oxo-olean-12-ene-30-oic acid possessing anti-HIV-1 activity. This compound shows less toxicity (CD₅₀ = 250 mcg/ml) as compared with the known anti-HIV preparation azidothymidine (CD₅₀ = 3.5 mcM) and elicits the expressed anti-HIV-1 activity of high effectiveness and inhibits accumulation of virus-specific protein p24 (ID₅₀ = 0.73 mcg/ml) that by 170-fold lower as compared with GA. This compound exceeds GA by the selectivity index (IS = 342.5) by 30-fold in culture cells MT-4 infected with the strain HIV-1/EVK. Glycopeptide in the concentration 0.80 mcg/ml (ID₉₀ = 0.80 mcg/ml) inhibits reproduction of virus by 90%. Anti-HIV-1 activity (inhibition of p24) of the proposed compound in the concentration 10 mcg/ml is similar with activity of azidothymidine in the dose 0.05 mcg/ml.

EFFECT: enhanced and valuable antiviral properties of compound.

3 tbl, 2 ex